Press "Enter" to skip to content

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to strengthen the long-term safety oversight of the Essure device following discontinuation of its U.S. sales

The FDA provides update on Essure postmarket review study as company prepares to halt sales of the device on December 31.

Original source:

Also Read:   FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer